Skip to content

Michael Schmertzler, Director at Ptc Therapeutics, sold PTCT on Aug 19, 2026

Data as of Oct 16

▼ SELL$389K5,335 shares at $72.86Michael Schmertzler DirectorPTCT Ptc Therapeutics, Inc.
Watch PTCT
Traded
Aug 19, 2026
Disclosed
Aug 21, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Michael Schmertzler, Director at Ptc Therapeutics, sold PTCT on Aug 19, 2026TRADEDDISCLOSED
PTCTSimilar stocks (XLV — its sector index fund), rebased to PTCT's price on the disclosure day
PTCT since disclosure
−15.2%
after the sale
Similar stocks (XLV) since disclosure
+1.2%
XLV — its sector index fund

Change in closing price from Aug 21, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLMichael Schmertzler DirectorPTCT Ptc Therapeutics, Inc.$50.4Kdisclosed Aug 21 · filed 1 day after the trade
  2. ▼ SELLMichael Schmertzler DirectorPTCT Ptc Therapeutics, Inc.$667Kdisclosed Aug 21 · filed 1 day after the trade
  3. ▼ SELLMichael Schmertzler DirectorPTCT Ptc Therapeutics, Inc.$172Kdisclosed Aug 21 · filed 1 day after the trade
  4. ▼ SELLMichael Schmertzler DirectorPTCT Ptc Therapeutics, Inc.$528Kdisclosed Aug 21 · filed 2 days after the trade

See every trade on PTCT →